Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
131.52
+0.26 (0.20%)
Nov 17, 2025, 3:13 PM EST - Market open
Novartis AG Revenue
Novartis AG had revenue of $14.36B in the quarter ending September 30, 2025, with 9.00% growth. This brings the company's revenue in the last twelve months to $56.37B, up 12.88% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$56.37B
Revenue Growth
+12.88%
P/S Ratio
4.53
Revenue / Employee
$742,880
Employees
75,883
Market Cap
255.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
NVS News
- 6 hours ago - The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - Newsfile Corp
- 4 days ago - New, effective anti-malaria drug could help fight rising resistance, says Novartis - Reuters
- 7 days ago - Novartis opens new plant in California to make cancer drugs - Reuters
- 13 days ago - New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewsWire
- 14 days ago - Meharry and Novartis Partner on HEART Initiative for Healthier Communities - Business Wire
- 17 days ago - Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript - Seeking Alpha
- 19 days ago - Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials - GlobeNewsWire
- 19 days ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha